NewsVandana Singh
Capricor Therapeutics
CAPR · NASDAQ
$6.61−$0.04 (−0.60%)TodayMarket closed ·
Prev close $6.65
Latest news
- Press releaseGlobe Newswire
Capricor Therapeutics Presents Positive HOPE-3 Open-Label Extension Data on Upper Limb Function in Duchenne Muscular Dystrophy at 2026 World Muscle Society Congress
- NewsHenry Khederian
Capricor Therapeutics Stock Surges: What's Going On?
- NewsAvi Kapoor
Hewlett Packard Enterprise, Capital Bancorp, FormFactor And Other Big Stocks Moving Higher On Wednesday
- Press releaseBusiness Wire
CAPR CLASS ACTION DEADLINE TONIGHT: Faruqi & Faruqi, LLP Reminds Capricor Investors of Securities Class Action Lawsuit Deadline on September 28, 2026
- Press releaseGlobe Newswire
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of September 28, 2026 in Capricor Therapeutics, Inc. Lawsuit - CAPR
- Press releaseGlobe Newswire
CAPR Investor Lawsuit: Capricor Therapeutics Sued for Securities Fraud on behalf of Investors with Losses – Contact BFA Law by September 28 Court Deadline
- Press releaseNewsfile
CAPR INVESTOR DEADLINE: Rosen Law Firm Reminds Capricor Therapeutics, Inc. Investors of September 28 Lead Plaintiff Deadline in Securities Class Action
- Press releaseNewsfile
CAPR DEADLINE: ROSEN, HIGHLY RECOGNIZED INVESTOR COUNSEL, Encourages Capricor Therapeutics, Inc. Investors to Secure Counsel Before Important September 28 Deadline in Securities Class Action - CAPR
- Press releaseGlobe Newswire
CAPR 2-DAY DEADLINE ALERT: Capricor Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Shareholder Class Action Lawsuit Before September 28, 2026 Deadline
- Press releaseGlobe Newswire
CAPR INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Reminds Capricor Investors of Securities Class Action Lawsuit Deadline on September 28, 2026
- Press releaseGlobe Newswire
CAPR FINAL DEADLINE: ROSEN, A SKILLED AND LEADING LAW FIRM, Encourages Capricor Therapeutics, Inc. Investors to Secure Counsel Before Important September 28 Deadline in Securities Class Action - CAPR
- Press releaseGlobe Newswire
CAPRICOR DEADLINE SEPTEMBER 28th: Bragar Eagel & Squire, P.C. Urges Capricor Therapeutics, Inc. Investors With Large Losses to Contact the Firm Before the September 28th Deadline
- Press releasePRNewswire
CAPR 3-DAY DEADLINE ALERT: Capricor Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Shareholder Class Action Lawsuit Before September 28, 2026 Deadline
- Press releaseGlobe Newswire
CAPR Stock Drop Alert: Capricor Therapeutics Stock Plummets 64% after Clinical Data Issues Revealed – BFA Law Notifies Investors of the Imminent September 28 Deadline
- Press releasePRNewswire
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Capricor Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines - CAPR
- Press releasePRNewswire
CAPR Deadline: CAPR Investors with Losses in Excess of $100K Have Opportunity to Lead Capricor Therapeutics, Inc. Securities Fraud Lawsuit
- Press releasePRNewswire
CAPR INVESTOR DEADLINE: Capricor Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Shareholder Class Action Lawsuit Before September 28 Deadline
- Press releasePRNewswire
SueWallSt Reminds Capricor Therapeutics Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of September 28, 2026 - CAPR
- Press releaseBusiness Wire
CAPR 5-DAY DEADLINE: Capricor Investors Have Opportunity to Lead Class Action - HBSS
- Press releasePRNewswire
CAPR Shareholder Alert: Investors With Losses May Seek to Lead the Class Action in Capricor Therapeutics Securities Lawsuit - Contact Levi & Korsinsky
- Press releaseGlobe Newswire
$CAPR Stock Notification: Capricor Therapeutics has been Sued for Securities Fraud after Clinical Data Issues Disclosed – Investors are Alerted to Contact BFA Law by September 28
- Press releaseGlobe Newswire
Portnoy Law Firm Announces Class Action on Behalf of Capricor Therapeutics, Inc. Investors
- Press releasePRNewswire
CAPR Class Action: Capricor Therapeutics Investors are Notified of the Upcoming September 28 Deadline in Ongoing Securities Fraud Class Action over Clinical Data
- Press releasePRNewswire
CAPR Investors Have Opportunity to Lead Capricor Therapeutics, Inc. Securities Fraud Lawsuit with SBS Law
- Press releasePRNewswire
Capricor Therapeutics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - CAPR
- Press releasePRNewswire
1 WEEK CAPR INVESTOR DEADLINE: Capricor Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
- Press releaseGlobe Newswire
Bragar Eagel & Squire, P.C. Urges Capricor Therapeutics, Inc. Investors With Large Losses to Contact the Firm Before the September 28th Deadline
- Press releasePRNewswire
CAPR 1-WEEK DEADLINE ALERT: Capricor Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Shareholder Class Action Lawsuit Before September 28 Deadline
- Press releaseGlobe Newswire
CAPR Loss Alert: Lose Money on Your Capricor Therapeutics Investment? BFA Law Reminds Investors of the Ongoing Securities Fraud Class Action to Recover Losses
- Press releaseGlobe Newswire
CAPR INVESTOR DEADLINE: Capricor Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Shareholder Class Action Lawsuit Before September 28, 2026 Deadline
- Press releasePRNewswire
Capricor Therapeutics Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against Capricor Therapeutics, Inc. - CAPR
- Press releasePRNewswire
Capricor Therapeutics, Inc. Stockholders with Significant Losses Should Contact Robbins LLP Before the Pending September 28, 2026 Lead Plaintiff Deadline
- Press releasePRNewswire
CAPR Stock Alert: Capricor Therapeutics, Inc. Reports Q2 Earnings Amid Ongoing Securities Class Action Lawsuit - Hagens Berman
- NewsAvi Kapoor
Yext Posts Upbeat Q2 Earnings, Joins Fervo Energy, MiniMed Group And Other Big Stocks Moving Higher On Tuesday
- Press releasePRNewswire
CAPR INVESTOR DEADLINE: Capricor Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Shareholder Class Action Lawsuit
- News
12 Health Care Stocks Moving In Wednesday's Intraday Session
- NewsAvi Kapoor
Abercrombie & Fitch Posts Upbeat Q2 Results, Joins Semtech, Summit Therapeutics And Other Big Stocks Moving Higher On Wednesday
- Press releaseGlobe Newswire
Capricor Therapeutics, Inc. (CAPR) Investors: Securities Fraud Class Action Filed, Contact Hagens Berman Before September 28, 2026 Lead Plaintiff Deadline
- NewsVandana Singh
Why Is Capricor Therapeutics Stock Trading Higher on Monday?
- NewsVandana Singh
Activist Investor Sounds Alarm on Capricor’s Cash Burn
- Press releasePRNewswire
Capricor Therapeutics, Inc. (CAPR) Investors: September 28, 2026 Lead Plaintiff Deadline in Class Action Lawsuit
- Press releasePRNewswire
CAPR Stock Alert: Capricor Therapeutics, Inc. (CAPR) Reports Q2 Earnings Amid Ongoing Securities Class Action Lawsuit - Hagens Berman
- Press releaseGlobe Newswire
CAPR Stock Alert: Capricor Therapeutics, Inc. (CAPR) Reports Q2 Earnings Amid Ongoing Securities Class Action Lawsuit – Hagens Berman
- NewsAvi Kapoor
H World Group Posts Upbeat Q2 Results, Joins Almonty Industries, Diana Shipping And Other Big Stocks Moving Higher On Monday
- News
Benzinga Bulls And Bears: Amazon, Microsoft, SpaceX
- Press releaseGlobe Newswire
Johnson Fistel, PLLP Investigates Claims on Behalf of Long-Term Shareholders of Atkore Inc. (ATKR), Axsome Therapeutics, Inc. (AXSM), Capricor Therapeutics, Inc. (CAPR), and CTO Realty Growth, Inc. (CTO)
- Press releaseGlobe Newswire
Johnson Fistel, PLLP Investigates Claims on Behalf of Long-Term Shareholders of Atkore Inc. (ATKR), Axsome Therapeutics, Inc. (AXSM), Capricor Therapeutics, Inc. (CAPR), and CTO Realty Growth, Inc. (CTO)
- NewsAvi Kapoor
Crude Oil Gains 1%; Macy's Reports Strong Q3 Results
- NewsAvi Kapoor
US Stocks Mixed; Dollar Tree Posts Upbeat Earnings
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.